# Fischer Medical Ventures share price today (Fischer Medical Ventures Ltd, NSE: FISCHER)

> Fischer Medical Ventures share price today: ₹24.63 at the NSE close on 3 November 2026, down 79.1% in a year. Fischer Medical Ventures (NSE: FISCHER) is worth ₹1,720 crore, trades at a P/E of 91.6 and has closed between ₹24.63 and ₹92.70 over the past 52 weeks. > Fischer Medical Ventures Ltd's share price, valuation and earnings point in different directions. The next one or two quarters should make it clearer. FISCHER · Chemicals - Inorganic · data as of 3 November 2026. Page: https://www.sectoralpha.in/stocks/fischer-medical-ventures-ltd

Sector Alpha also publishes a daily newsletter that explains one Indian stock at a time: https://newsletter.sectoralpha.in/?utm_source=sectoralpha&utm_medium=ai_text&utm_campaign=llms

## Key numbers

- Price: ₹24.63 (−79.1% in a year)
- P/E: 91.6× (higher than 55% of the last 8.1 years)
- Revenue (Jun 2026): ₹0.7 Cr (−84.1% on a year ago)
- Profit (Jun 2026), incl. one-off: −₹3.5 Cr (one-off item, see below)
- Operating margin: −261.1% (−269.5 points on a year ago)
- ROCE: −2%, FY26

The main question: the share price moved −79.1% in a year while yearly earnings per share moved −1,700.0%. The difference came from the market paying a higher multiple. ## What is the Fischer Medical Ventures share price today? Fischer Medical Ventures Ltd's share price was ₹24.63 at the close on 3 November 2026. It has been falling for 48 weeks. That is 39.4% below its average price over the last 200 trading days. In the last 52 weeks it traded between ₹25 and ₹93, and at that close it was at the low of that range. Over the past 13 weeks it has done worse than the NIFTY 500, and it has been behind for 9 weeks running. Over the last 11 years the share price moved +11,095% while the NIFTY 500 moved +241%, so it is ahead of the index over that whole period. It was last ahead over 13 weeks in the week of 11 September 2026. The chart above shows the 13-week comparison for every week. This page treats a rise as over when the price closes below its 200-day average on two Fridays in a row. ## What changed at Fischer Medical Ventures this quarter? Three changes stood out: lowest operating margin in 14 quarters, foreign funds (FIIs) raised their stake for 4 quarters in a row and number of shareholders up 97% in a year. 1. Lowest operating margin in 14 quarters Operating margin was -261.1% in the June 2026 quarter, against 8.4% a year earlier. 2. Foreign funds (FIIs) raised their stake for 4 quarters in a row From 4.9% to 6.7% of the company by the September 2026 quarter. 3. Number of shareholders up 97% in a year 25,676 shareholders in the September 2026 quarter, against 13,054 a year earlier. ## What are Fischer Medical Ventures' latest quarterly results? For April to June 2026 (the quarter ended 30 June 2026), Fischer Medical Ventures reported revenue of ₹0.72 crore, down 84.1% from ₹4.54 crore a year earlier, and a loss of ₹3.50 crore. ### Fischer Medical Ventures results: April to June 2026 against a year earlier

| Measure | April to June 2026 | April to June 2025 | Change |
| --- | --- | --- | --- |
| Revenue | ₹0.72 crore | ₹4.54 crore | −84.1% |
| Profit | loss of ₹3.50 crore | loss of ₹0.61 crore | n/a |
| Earnings per share | ₹−0.05 | ₹−0.01 | n/a |
| Operating margin | −261.1% | 8.4% | −269.5 points |

The next results, for July to September 2026, are due by 14 November 2026: listed companies must publish quarterly results within 45 days of the quarter's end (60 days for the January to March quarter). The newest call in our records is from 7 November 2025, about July to September 2025; a call about these results is not in our records yet. (From the company's reported quarterly results (quarter ended 30 June 2026). Revenue and profit in ₹ crore.)

## What is the Fischer Medical Ventures share price history? Fischer Medical Ventures closed at ₹24.63 on 3 November 2026, down 79.1% from ₹117.65 a year earlier (31 October 2025) and up 160.9% over five years. Its highest weekly close since March 2016 was ₹117.65 on 31 October 2025. ### Fischer Medical Ventures share price: then and now

| When | Close | Change to 3 Nov 2026 |
| --- | --- | --- |
| 1 week ago · 23 Oct 2026 | ₹24.95 | −1.3% |
| 1 month ago · 1 Oct 2026 | ₹33.50 | −26.5% |
| 6 months ago · 30 Apr 2026 | ₹38.08 | −35.3% |
| 1 year ago · 31 Oct 2025 | ₹117.65 | −79.1% |
| 3 years ago · 9 Nov 2023 | ₹8.15 | +202.2% |
| 5 years ago · 12 Nov 2021 | ₹9.44 | +160.9% |
| 10 years ago · 7 Nov 2016 | ₹0.18 | +13,583.3% |
| Earliest weekly close in our records · 16 Mar 2016 | ₹0.22 | +11,095.5% |
| Highest weekly close since March 2016 · 31 Oct 2025 | ₹117.65 | −79.1% |
| Lowest weekly close since March 2016 · 16 May 2017 | ₹0.16 | +15,293.8% |
| 52-week high (weekly close) · 7 Nov 2025 | ₹92.70 | −73.4% |
| 52-week low (weekly close) · 3 Nov 2026 | ₹24.63 | 0.0% |

Weekly closing prices, adjusted for splits and bonuses so every price is on today’s share count. Each change is the move from that price to the 3 Nov 2026 close. A day's intraday high or low can go beyond these weekly closes. (396 weekly closes from 16 March 2016 to 3 November 2026.)

## What is the latest news on Fischer Medical Ventures? 3 Nov 2026: Fischer Medical Ventures closed at ₹24.63, down 1.3% on the week and down 26.5% on the month. 22 Sep 2026: ex-date for a dividend of ₹0.05 a share. ### Earlier

- Results for April to June 2026: Revenue down 84.1% on a year earlier. - 7 Nov 2025: Fischer Medical Ventures held its results call for July to September 2025. - 12 Sep 2025: Share split: face value cut from ₹10 to ₹1 a share (ex-date). ## What dividend does Fischer Medical Ventures pay? Fischer Medical Ventures paid ₹0.05 a share in regular dividends in the 12 months to 4 November 2026 (1 payment), a yield of 0.20% at the ₹24.63 close on 3 November 2026. The last was a dividend of ₹0.05 a share, ex-date 22 September 2026. ### Fischer Medical Ventures dividends since 1 April 2021

| Ex-date | Dividend per share | Type |
| --- | --- | --- |
| 22 Sep 2026 | ₹0.05 | Dividend |
| 22 Sep 2025 | ₹0.01 | Dividend |

Amounts as the company declared them on the NSE. A dividend goes to whoever owns the shares before the ex-date. The record date is the same day as the ex-date for every payment here. 1 of 5 Of the last 5 financial years, years with an NSE dividend record

Not in its latest year. Fischer Medical Ventures Ltd paid out 0% of its profit as dividends in FY26. It did pay a dividend in 1 of its last 11 reported years, so there is a history but no current dividend. (From the NSE corporate-actions record, read 4 November 2026.)

## What did Fischer Medical Ventures management say on the latest results call? On the call for July to September 2025, held on 7 November 2025, Fischer Medical Ventures' management spoke about the quarter; the main points are below. > “We are at the forefront of taking advantage of these transformative government programs and are reaping the benefits going forward”
> on the call for July to September 2025

Source: [the call transcript](https://files.tijorifinance.com/insight/india/2768/Conference Call/CC-Nov25.pdf). (From the call for July to September 2025, 7 November 2025. The April to June 2026 results are out since, so this part may be out of date until we update it.)

## Which stock lists is Fischer Medical Ventures on? Fischer Medical Ventures is on one of our India lists: Penny stocks. [Penny stocks](https://www.sectoralpha.in/penny-stocks-india)

## Is Fischer Medical Ventures profitable? Fischer Medical Ventures Ltd posted a net loss of ₹3.5 Cr in the Jun 2026 quarter. That quarter includes a one-off gain bigger than its revenue, so the comparison with last year does not reflect normal business. The full FY26 year was a loss of ₹10.0 Cr. That loss is 486.1% of the quarter's revenue. The same quarter a year earlier lost ₹0.6 Cr. 6 of the last 12 reported quarters were loss-making. For the full year, FY26 profit was −₹10.0 Cr (−1,100.0% on the year before). Read this profit with care: at −₹3.5 Cr it is bigger than the quarter's whole revenue of ₹0.7 Cr. No business earns more than it takes in from sales, so this is a one-off item (for example a debt settlement, a tax write-back or an asset sale), not money the business earned. The underlying business is running at a −261.1% operating margin. The jump on last year, and any P/E built on this profit, come from the one-off, not from a real turn in earnings. ## How much revenue does Fischer Medical Ventures make, and is it growing? Fischer Medical Ventures Ltd reported ₹0.7 Cr of revenue in the Jun 2026 quarter, −84.1% on the same quarter a year earlier. The last full year, FY26, came in at ₹17.0 Cr. The last four reported quarters add to ₹13.6 Cr. A growth rate over several years is not shown, because there are too few years of figures to work one out properly. FY26 revenue was ₹17.0 Cr, +240.0% on the year before. Is growth speeding up? Revenue over the last 12 months grew +39.1%, against +8.5% a year over the last 8 quarters (accelerating). ## How much of every ₹100 of sales does Fischer Medical Ventures keep? Fischer Medical Ventures Ltd's operating margin was −261.1% in the Jun 2026 quarter, 269.5 percentage points lower than the same quarter a year ago. Across 10 years it has been between −300.0% and 11.0%. The latest quarter is within that range. Why the margin moved: operating margin changed −269.5 percentage points on the year while gross margin changed −24.2 points. So the drop came mostly from costs below the gross margin, such as staff and overheads, measured against sales. ## Is Fischer Medical Ventures' profit turning into cash? Fischer Medical Ventures Ltd's cash-flow history is too short to judge how much of its profit turns into cash. In FY26 its operations used ₹3.0 Cr of cash, against −₹10.0 Cr of profit. After ₹11.0 Cr of spending on assets, free cash was −₹14.0 Cr: it spent more than its operations brought in. Cash-flow figures here are yearly, because quarterly cash statements are not published, so this section changes once a year. What to look at next: the main use of cash is spending on assets. The next section checks what that spending is building. ## Where does Fischer Medical Ventures' cash go? Fischer Medical Ventures Ltd's customer, stock and supplier day counts come out in the thousands of days on sales this small (₹17.0 Cr in FY26), so no cash-cycle chart is drawn and this section looks at its spending on assets instead. It spent ₹12.0 Cr on assets over the last 3 years. Averaged over those years that is 23.5% of FY26 revenue a year. Spending on assets: ₹12.0 Cr over the last 3 years, against ₹1.0 Cr of depreciation (the yearly wear and tear on existing assets). So it is building well beyond replacing what wears out. Work still in progress is ₹0.0 Cr (FY26): assets paid for that are not earning yet. In short: the cash is going into new capacity, not getting stuck in the daily cycle. The question is whether the new capacity earns. ## What is Fischer Medical Ventures' P/E ratio, and how does it compare with its own history? Fischer Medical Ventures Ltd's P/E is 91.6×, in the middle of its own history: higher than 55% of past readings. Its usual P/E (the middle reading) is 47.4×, over 8.1 years of weekly prices. This compares the share price with the company’s own past. It does not say what the business is worth. Why the multiple is where it is: over the past year earnings per share moved −1,700.0% while the price moved −79.1%. The price did better than earnings, which pushed the multiple up within its own range. Where the price move came from: over 5 years the price moved +21.1% a year; about −15.5% a year came from earnings growth and about +36.6 percentage points from the multiple (the market paying more). The split is approximate (price return minus earnings growth). It shows how much of the move came from the market paying a different multiple. In short: the multiple is about average against its own past, so the earnings trend underneath matters more than the multiple. ## Is the Fischer Medical Ventures business getting better or worse? Fischer Medical Ventures Ltd's business trend cannot be read yet. There are fewer than eight usable quarters of growth figures, so there is not enough history to read the trend. This is based on 8 quarters of 2 measures, with some gaps. Why it matters: with too little history, we say so rather than guess a direction. The latest quarter’s profit includes a one-off item bigger than the normal business, so the profit line is shown but does not count in this reading. One or more growth lines have an extreme jump caused by comparing with a near-zero or loss-making quarter. Those jumps are capped before reading and drawn at the edge of the chart, so one odd quarter does not decide the result. There are fewer than eight usable quarters, so this page does not guess a direction from so little history. ## How much does Fischer Medical Ventures earn on its capital? Fischer Medical Ventures Ltd earned a ROCE of −2% in FY26. That is up from a low of −350% in FY17. Its return on capital used (ROIC) is left out: on sales this small it reads 40%, a number that says nothing useful about the business. It comes from a −58.8% net margin and 0.04× asset turnover (sales divided by assets). Why the return is what it is (FY26): a −58.8% net margin × 0.04× asset turnover × 1.15× leverage (assets divided by equity) ≈ −2.7% on equity. The margin does its share; borrowing plays a small part, so this return is earned, not borrowed. ## Does Fischer Medical Ventures have too much debt? Fischer Medical Ventures Ltd has total debt of ₹107 Cr against shareholder equity of ₹387 Cr as of Jun 2026, so its debt is 0.28× its equity, which is very little. So the returns on this page come from the business, not from borrowed money. ## What is the Fischer Medical Ventures shareholding pattern? Promoters cut their stake in Fischer Medical Ventures Ltd by 11.8 percentage points over 8 quarters, the biggest change among its owners. Promoters now own 63.1% of the company. Foreign institutions moved +1.6 points over the same period, to 6.7%. This uses the four owner groups that companies report every quarter; nothing is guessed between filings. Over the last two years: Promoters: −11.8 points over 8 quarters, to 63.1%; Foreign institutions: +1.6 points over 8 quarters, to 6.7%; Domestic institutions: −0.4 points over 8 quarters, to 1.3%. Why the owners changed: promoters drove it (−11.8 points), with the other side taken by foreign institutions (+1.6 points). They reduced their stake. ## How far is Fischer Medical Ventures from balance-sheet trouble? For Fischer Medical Ventures Ltd, the Z-score is not available, so we say so rather than guess one. It estimates how far the balance sheet is from trouble; it is not a forecast of failure. The debt, cash-flow and return sections show the balance-sheet figures we do have, each with its own date. ## How does Fischer Medical Ventures rank in its industry? 26.6 out of 100, rank 9 of 9 in Chemicals - Inorganic, with 71% of the evidence available. Fischer Medical Ventures Ltd scores 26.6 out of 100 against the 9 companies it is compared with in Chemicals - Inorganic, ranking 9. The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. The four parts add up to the total exactly: 14.2 + 1.8 + 8.9 + 1.7 = 26.6. This is the same number shown on the industry page; it is worked out once for the whole group and read here. What would change it: The score would fall if profit growth turns negative or margins stop improving while the share price lags its sector. ## Which companies is Fischer Medical Ventures compared with? Fischer Medical Ventures ranks 9 of 9 Chemicals - Inorganic companies on the 4-Factor Sector Score, with 26.6 out of 100. 1. [Deepak Nitrite Ltd](https://www.sectoralpha.in/stocks/deepak-nitrite-ltd) DEEPAKNTR · quiet · Most evidence points up · 100% evidence 70.0 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 32.7/35 · Revenue 23.8% · Profit 100% · Operating margin change 9 points · 100% evidence Capital efficiency 12.4/25 · ROCE 11.4% · Operating margin 20% · 100% evidence Valuation 15.6/20 · P/E 19.4× · PEG 0.89 · 100% evidence Relative strength 9.3/20 · Lead over its industry -6.1% · Lead over NIFTY 500 -1.7% · 1 year -12.1% · 100% evidence · 0 of 12 weeks ahead Exact sum: 32.7 + 12.4 + 15.6 + 9.3 = 70 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 2. [Indo Borax & Chemicals Ltd](https://www.sectoralpha.in/stocks/indo-borax-chemicals-ltd) INDOBORAX · leader · Evidence leans up · 96% evidence 59.6 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 24.8/35 · Revenue 28.9% · Profit 47.4% · Operating margin change 5 points · 88% evidence Capital efficiency 18.6/25 · ROCE 15.4% · Operating margin 28% · 100% evidence Valuation 4.4/20 · P/E 25.5× · PEG 1.77 · 100% evidence Relative strength 11.8/20 · Lead over its industry 19.3% · Lead over NIFTY 500 22.2% · 1 year 44% · 100% evidence · 11 of 12 weeks ahead Exact sum: 24.8 + 18.6 + 4.4 + 11.8 = 59.6 · What this means: Earnings, capital efficiency and relative strength all agree. The open questions are about management, upcoming events and risks. 3. [Ganesh Benzoplast Ltd](https://www.sectoralpha.in/stocks/ganesh-benzoplast-ltd) GANESHBE · losing its lead · Evidence leans up · 74% evidence 57.1 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 21.1/35 · Revenue 13.1% · Profit 87.2% · Operating margin change -7 points · 88% evidence Capital efficiency 11.2/25 · ROCE 14.5% · Operating margin 23% · 100% evidence Valuation 16.1/20 · P/E 9.7× · PEG 0.25 · 65% evidence Relative strength 8.7/20 · Lead over its industry n/a · Lead over NIFTY 500 -3.7% · 1 year 1.9% · 25% evidence · 9 of 12 weeks ahead Exact sum: 21.1 + 11.2 + 16.1 + 8.7 = 57.1 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 4. [Tanfac Industries Ltd](https://www.sectoralpha.in/stocks/tanfac-industries-ltd) TANFACIND · leader · Evidence leans up · 76% evidence 57.0 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 12.0/35 · Revenue 13.2% · Profit -29.2% · Operating margin change -1 points · 83% evidence Capital efficiency 16.5/25 · ROCE 23.9% · Operating margin 15% · 95% evidence Valuation 8.5/20 · P/E 112× · PEG n/a · 15% evidence Relative strength 20.0/20 · Lead over its industry 44.2% · Lead over NIFTY 500 48.6% · 1 year 82.1% · 100% evidence · 12 of 12 weeks ahead Exact sum: 12 + 16.5 + 8.5 + 20 = 57 · What this means: Relative strength against the index is 48.6%, and revenue and profit growth are weak. 5. [J.G.Chemicals Ltd](https://www.sectoralpha.in/stocks/jgchemicals-ltd) JGCHEM · leader · Evidence leans up · 63% evidence 56.9 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 21.9/35 · Revenue 24% · Profit 16.4% · Operating margin change 2 points · 83% evidence Capital efficiency 15.5/25 · ROCE 17.7% · Operating margin 11% · 76% evidence Valuation 7.5/20 · P/E 29.3× · PEG n/a · 50% evidence Relative strength 12.0/20 · Lead over its industry n/a · Lead over NIFTY 500 33.3% · 1 year 31.2% · 25% evidence · 12 of 12 weeks ahead Exact sum: 21.9 + 15.5 + 7.5 + 12 = 56.9 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 6. [Sree Rayalaseema Hi-Strength Hypo Ltd](https://www.sectoralpha.in/stocks/sree-rayalaseema-hi-strength-hypo-ltd) SRHHYPOLTD · breaking out · Evidence leans up · 81% evidence 52.0 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 15.5/35 · Revenue 7.6% · Profit 1.1% · Operating margin change -1 points · 88% evidence Capital efficiency 12.9/25 · ROCE 13.7% · Operating margin 14% · 100% evidence Valuation 12.9/20 · P/E 8.4× · PEG 1.29 · 100% evidence Relative strength 10.7/20 · Lead over its industry n/a · Lead over NIFTY 500 2.9% · 1 year -12.1% · 25% evidence · 8 of 12 weeks ahead Exact sum: 15.5 + 12.9 + 12.9 + 10.7 = 52 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 7. [POCL Enterprises Ltd](https://www.sectoralpha.in/stocks/pocl-enterprises-ltd) POEL · Evidence leans down · 69% evidence 46.0 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 7.8/43.75 · Revenue 4.6% · Profit -2% · Operating margin change -3 points · 88% evidence Capital efficiency 19.8/31.25 · ROCE 26.6% · Operating margin 2.5% · 100% evidence Valuation 18.4/25 · P/E 12.2× · PEG 0.71 · 65% evidence Relative strength: no reading this week · its 20 points are shared across the other three Exact sum: 7.8 + 19.8 + 18.4 = 46 (no relative-strength reading this week; its 20 points are shared across the other three) · What this means: There is no relative-strength reading for this week, so the score is built from earnings, capital efficiency and valuation alone. 8. [Archean Chemical Industries Ltd](https://www.sectoralpha.in/stocks/archean-chemical-industries-ltd) ACI · quiet · Most evidence points down · 90% evidence 29.8 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 6.9/35 · Revenue 6% · Profit -43.3% · Operating margin change -3 points · 100% evidence Capital efficiency 9.6/25 · ROCE 7.4% · Operating margin 24% · 100% evidence Valuation 8.5/20 · P/E 54.7× · PEG n/a · 50% evidence Relative strength 4.8/20 · Lead over its industry -18.3% · Lead over NIFTY 500 -14% · 1 year -33.1% · 100% evidence · 0 of 12 weeks ahead Exact sum: 6.9 + 9.6 + 8.5 + 4.8 = 29.8 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 9. Fischer Medical Ventures Ltd this page FISCHER · quiet · Most evidence points down · 71% evidence 26.6 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 14.2/35 · Revenue 39.1% · Profit -80% · Operating margin change -269.5 points · 65% evidence Capital efficiency 1.8/25 · ROCE -1.6% · Operating margin -261.1% · 100% evidence Valuation 8.9/20 · P/E 58.4× · PEG n/a · 15% evidence Relative strength 1.7/20 · Lead over its industry -36.8% · Lead over NIFTY 500 -33.5% · 1 year -79% · 100% evidence · 2 of 12 weeks ahead Exact sum: 14.2 + 1.8 + 8.9 + 1.7 = 26.6 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. Missing figures are not scored as bad. They lower the confidence and pull the final score toward the middle. Relative strength counts only when the company has a reading for this week; with no reading, that factor is left out and its 20 points are shared across the other three in proportion. PEG is not shown when the ratio cannot mean anything: the company must be making a profit, its price-to-earnings must be positive, and its three-year earnings growth must fall between 5% and 60%. Dividing a price multiple by a loss, or by growth measured off a tiny base, produces a number that looks precise and tells you nothing. Under relative strength, one mark per week shows the last 12 weeks: a mark is filled where the company led NIFTY 500 by 5% or more over the 13 weeks ending that week, which is the same test used everywhere on this site. Price stage places the company on the same six-step path the industry is placed on (basing, turning, breaking out, leader, fading, asleep), read from how many weeks running it has led NIFTY 500 and whether that lead is growing or shrinking. It describes where the share price stands, not the direction of earnings, and it is not a recommendation; it is left blank for a company whose weekly history is too short or too stale to read. The figures in this ranking come from the industry comparison: results through the Sep 2026 quarter, and the P/E at that quarter's end. The sections above use the latest weekly price, so a P/E or return there can differ a little from the one here. The stage words in this ranking (such as losing its lead or breaking out) describe the lead over the index, not the price phase in the price section. Related companies: [Chemicals - Inorganic](https://www.sectoralpha.in/sectors/chemicals-inorganic), all 9 compared on one page. ## Which companies are close to Fischer Medical Ventures in size? Fischer Medical Ventures is the 5th largest of 9 Chemicals - Inorganic companies on Sector Alpha by market value (scores of 30 October 2026). Just above it: Tanfac Industries, Archean Chemical Industries and J.G.Chemicals. Just below it: Indo Borax & Chemicals, Sree Rayalaseema Hi-Strength Hypo and Ganesh Benzoplast. ### Chemicals - Inorganic companies close in size

1. [Tanfac Industries Ltd](https://www.sectoralpha.in/stocks/tanfac-industries-ltd) ₹7,571 crore
2. [Archean Chemical Industries Ltd](https://www.sectoralpha.in/stocks/archean-chemical-industries-ltd) ₹5,460 crore
3. [J.G.Chemicals Ltd](https://www.sectoralpha.in/stocks/jgchemicals-ltd) ₹2,204 crore
4. Fischer Medical Ventures Ltd ₹1,732 crore
5. [Indo Borax & Chemicals Ltd](https://www.sectoralpha.in/stocks/indo-borax-chemicals-ltd) ₹1,248 crore
6. [Sree Rayalaseema Hi-Strength Hypo Ltd](https://www.sectoralpha.in/stocks/sree-rayalaseema-hi-strength-hypo-ltd) ₹833 crore
7. [Ganesh Benzoplast Ltd](https://www.sectoralpha.in/stocks/ganesh-benzoplast-ltd) ₹634 crore

[All 9 Chemicals - Inorganic companies, largest first](https://www.sectoralpha.in/sectors/chemicals-inorganic#all-companies)

### Companies close in size in other industries

1. [Gaja Alternative Asset Management Ltd](https://www.sectoralpha.in/stocks/gaja-alternative-asset-management-ltd) ₹1,735 crore
2. [S H Kelkar & Company Ltd](https://www.sectoralpha.in/stocks/s-h-kelkar-company-ltd) ₹1,735 crore · Chemicals - Others
3. Fischer Medical Ventures Ltd ₹1,732 crore
4. [Vidya Wires Ltd](https://www.sectoralpha.in/stocks/vidya-wires-ltd) ₹1,729 crore · Electric Equipment - General
5. [Kothari Industrial Corporation Ltd](https://www.sectoralpha.in/stocks/kothari-industrial-corporation-ltd) ₹1,728 crore · Trading

## What else do people ask about Fischer Medical Ventures? ### What is Fischer Medical Ventures's share price today? Fischer Medical Ventures Ltd's share price is ₹24.63, −79.1% over the past year. The whole company is worth ₹1,720 Cr on the market. It is at its lowest price of the past 52 weeks (range ₹25 to ₹93), 39.4% below its 200-day average. The price has been falling for 48 weeks (as of 3 November 2026). ### What were Fischer Medical Ventures's latest quarterly results? Fischer Medical Ventures Ltd reported revenue of ₹0.7 Cr and a net loss of ₹3.5 Cr for the Jun 2026 quarter. Earnings per share were −₹0.05. The operating margin was −261.1%, 269.5 percentage points lower than a year earlier (as of 3 November 2026). ### What is Fischer Medical Ventures's market cap? Fischer Medical Ventures Ltd's market capitalisation is ₹1,720 Cr at a share price of ₹24.63. Market cap is the share price times the number of shares, so it changes whenever the price moves (as of 3 November 2026). ### How is Fischer Medical Ventures performing? Fischer Medical Ventures Ltd's share price has been falling for 48 weeks. Over the past 13 weeks it has done worse than the NIFTY 500, for 9 weeks running. This describes what the data did, not a rating (as of 3 November 2026). ### Will Fischer Medical Ventures's share price go up? This page does not forecast Fischer Medical Ventures Ltd's share price. What it shows instead: the share price is ₹24.63, and it has been falling for 48 weeks. Its P/E of 91.6× is higher than 55% of its own last 8 years (as of 3 November 2026). ### Does Fischer Medical Ventures have too much debt? No, Fischer Medical Ventures Ltd has little debt: its debt is 0.14× its equity, and its operating profit is −2 times its interest bill. FY26 borrowings were ₹46.0 Cr against equity of ₹338 Cr. So the returns on this page come from the business, not borrowed money (as of 3 November 2026). ### Where is Fischer Medical Ventures in its business cycle? Fischer Medical Ventures Ltd's FY26 operating margin was −50.0%, against a 10-year range of −300.0% to 11.0%: the middle of its own range, neither a peak nor a low. The latest quarter was −261.1%. Comparing margins with a company's own long history is a good way to see where it is in its cycle (as of 3 November 2026). ### What could break the Fischer Medical Ventures story? The main question: the share price moved −79.1% in a year while yearly earnings per share moved −1,700.0%. The difference came from the market paying a higher multiple. On price, this page treats a rise as over when the share price closes below its 200-day average on two Fridays in a row (as of 3 November 2026). ### Is Fischer Medical Ventures a stock worth studying right now? What the numbers show: Fischer Medical Ventures Ltd's share price, valuation and earnings point in different directions. The next one or two quarters should make it clearer. The main open question: whether earnings grow into a price that has already moved. Every number on this page is worked out by code from the published figures, with no forecasts and no price opinions (as of 3 November 2026). ## Lists

- Penny stocks: https://www.sectoralpha.in/penny-stocks-india

This is research, not advice. We’re not SEBI-registered.